Semaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022

Description: Semaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022

Summary

GlobalData has released its new report, “Semaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs.

Semaglutide is a long-acting GLP-1 analog being developed by Novo Nordisk, currently in Phase III clinical trials. Two Bristol-Myers Squibb medicines (short-acting Byetta and long-acting Bydureon), Novo Nordisk's long-acting Victoza and Sanofi's short-acting Lyxumia are marketed drugs in the same class of treatment for type 2 diabetes.

Scope

- Overview of type 2 diabetes, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Semaglutide including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Semaglutide for the top ten countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for type 2 diabetes
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Semaglutide performance
- Obtain sales forecast for Semaglutide from 2012-2022 in top ten countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China)

Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Prognosis
3.1.4 Quality of Life
3.2 Symptoms
4 Disease Management
4.1 Treatment Overview
4.1.1 Diagnosis and Referrals
4.1.2 Treatment Guidelines
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
6 Opportunity and Unmet Need
6.1 Overview
6.2 Unmet Needs
6.2.1 Drugs Providing Sustained Glycemic Control
6.2.2 Drugs with Non-Glycemic Benefits
6.2.3 Increased Patient Compliance
6.2.4 Drugs with Improved Side-Effect Profiles
6.2.5 Earlier Diagnosis
6.3 Unmet Needs Gap Analysis
6.4 Oral Therapy with Sustainable Efficacy
6.5 Oral Therapy Offering Weight Loss
6.6 Cardio-metabolic Therapy
6.7 Promotion of Type 2 Diabetes Drugs in Emerging Markets
7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development
8 Semaglutide
8.1 Overview
8.2 Efficacy
8.3 Safety
8.4 Potential Clinical Positioning
8.5 Potential Commercial Positioning
8.6 Pricing and Reimbursement
8.7 SWOT Analysis
8.8 Forecast
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Diagnosed Type 2 Patients
9.4.2 Percent Drug-Treated Patients
9.4.3 General Pricing Assumptions
9.4.4 Generic Erosion
9.4.5 Pricing of Pipeline Agents
9.5 Physicians and Specialists Included in this Study
9.6 About the Authors
9.6.1 Analyst II - CVMD
9.6.2 Therapy Director - CVMD and Infectious Disease
9.6.3 Global Head of Healthcare
9.7 About Us
9.8 Disclaimer

1.1 List of Tables
Table 1: Symptoms of Type 2 Diabetes
Table 2: Diagnostic Tests and Typical Criteria for Type 2 Diabetes
Table 3: Treatment Guidelines for Type 2 Diabetes
Table 4: Most-Prescribed Drugs (Following Metformin and Sulfonylureas) for Type 2 Diabetes by Class in the Global Markets, 2012
Table 5: Leading Branded Treatments for Type 2 Diabetes, 2012
Table 6: Overall Unmet Needs - Current Level of Attainment
Table 7: Clinical Unmet Needs - Gap Analysis, 2013
Table 8: Type 2 Diabetes - Phase Pipeline, 2012
Table 9: Comparison of Therapeutic Classes in Development for Type 2 Diabetes, 2012
Table 10: Product Profile - Semaglutide
Table 11: Semaglutide SWOT Analysis, 2012
Table 12: Global Sales Forecasts ($m) for Semaglutide, 2012-2022
Table 13: Number of High-Prescribing Physicians Surveyed

1.2 List of Figures
Figure 1: ADA/EASD General Recommendations for Antihyperglycemic Therapy
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Type 2 Diabetes, 2012-2022

Ordering:

Order Online - [http://www.researchandmarkets.com/reports/2706399/](http://www.researchandmarkets.com/reports/2706399/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- Product Name: Semaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022
- Web Address: http://www.researchandmarkets.com/reports/2706399/
- Office Code: SCD2UVH2

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 3495</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 6990</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 10485</td>
<td></td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ________________________________
Job Title: __________________________________
Organisation: ______________________________
Address: ___________________________________
City: ______________________________________
Postal / Zip Code: ___________________________
Country: ___________________________________
Phone Number: _______________________________
Fax Number: _________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World